Flurandrenolide

Mechanism :

Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A₂ inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid.
Flurandrenolide has intermediate range potency.

Indication :

• Corticosteroid-responsive dermatoses

Contraindications :

Hypersensitivity to flurandrenolide or any component of the formulation; lesions exuding serum or in intertriginous areas.

Dosing :

Adverse Effect :

Burning sensation, Acne vulgaris, acneiform eruptions, allergic contact dermatitis, atrophic striae, folliculitis, hypopigmentation, hypertrichosis, maceration of the skin, miliaria, perioral dermatitis, pruritus, skin atrophy, xeroderma, Local irritation, Secondary infection.

Interaction :

Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.
Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib.
Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.
Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.
Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.
Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine.

Hepatic Dose :